Related Experiment Video
Updated: Jan 3, 2026

A TNBS-Induced Rodent Model to Study the Pathogenic Role of Mechanical Stress in Crohn's Disease
Published on: March 1, 2022
Tissue factor in ulcerative colitis, with and without concomitant primary sclerosing cholangitis.
Johan Vessby1, Maria Lampinen1, Mikael Åberg2
1Department of Medical Sciences, Gastroenterology Research Group, Uppsala University, Uppsala, Sweden.
Tissue factor (TF) expression differs between ulcerative colitis (UC) and primary sclerosing cholangitis with UC (PSC-UC). Stromal TF may serve as a novel marker for colonic inflammation in PSC-UC.
Area of Science:
- Gastroenterology
- Immunology
- Oncology
Background:
- Ulcerative colitis (UC) with primary sclerosing cholangitis (PSC) presents a unique phenotype (PSC-UC) associated with increased colorectal cancer risk.
- Current PSC-UC diagnosis relies solely on clinical observation.
- Tissue factor (TF) shows promise in UC diagnostics and colorectal cancer prognostication.
Purpose of the Study:
- To investigate TF expression in an inflammatory bowel disease (IBD) cohort.
- To differentiate TF expression patterns between UC and PSC-UC patients.
Main Methods:
- Immunohistochemistry was used to analyze TF expression in colonic biopsies from UC, PSC, and healthy control groups.
- Flow cytometry was employed to confirm mononuclear cell contribution to TF expression.
Main Results:
- TF was localized in subepithelial pericryptal sheath cells, mononuclear cells, and intestinal stroma.
- Unlike UC, PSC-UC showed low TF activity despite inflammation.
- Stromal TF positivity was specifically observed during active inflammation.
Conclusions:
- The findings suggest a distinct pathogenesis in PSC-UC compared to classical UC, characterized by a different inflammatory environment.
- Stromal TF is identified as a potential new biomarker for colonic inflammation.
Related Concept Videos
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Peptic Ulcer Disease II: Pathophysiology
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
Drugs for Treatment of Ulcerative Colitis in IBD
Gastritis-II: Pathophysiology
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...

